TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: number of patients undergoing complete unsedated or slightly sedated colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vitiligo life quality index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of metaphase 2 oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Assessment of tolerability by investigator on a 4-point scale
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with clinically relevant findings in electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate to thal-dex induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free survival (PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen consumption rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hgb A1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of Life (QOL) questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Post-operative Pain
Endpoint domain: Adverse events/effects
Primary endpoint: Early Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Late Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Average Total Dose Per Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Pancreatic Insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Sputum IL-17 Neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite of Memory t Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Composite of Executive Function t Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subclinical atherosclerosis (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global- and health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of TRUS Robot and 3-D TRUS navigation software
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capability measured by Timed Up and Go test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait and balance performance measured by Berg Balance Scale (BBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Omigapil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time at Which Cmax Was Apparent (Tmax) of Omigapil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to 8h Post-dose (AUC0-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of orotracheal intubations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: In vivo Adipose Cell Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delayed Phase Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocrine outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in DNA methylation in genes associated with inflammation and colon carcinogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in minutes spent in moderate and vigorous intensity physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in minutes spent in moderate and vigorous intensity leisure activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in cognitive functions after exercise
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in motor functions after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antero-posterior stability of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical responses associated with oral 5-azacitidine and romidepsin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity for detection of B. pseudomallei
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of jejunal placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Satisfaction with the treatment at 12 month follow up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in menstrual status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical dilatation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correlation between fetal hiccups and cardiotocography parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of glasdegib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of glasdegib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in clinical laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in the QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) for Single Dose of 10 mg Exenatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) for Single Dose of 10 mg Exenatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in propulsion symmetry at self-selected gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of Blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of platelet abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of coagulation abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of thrombin abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Triple Aim Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peritoneal fibrinolytic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with local or distant recurrence or second colorectal cancer or death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: gastric residual at induction of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: aesthetic evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain after TKA measured by pain survey on Focusmotion app
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain after TKA measured by Washington University specific survey
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase and function of peripheral regulatory T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in MDS-UPDRS-IV score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of screened patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: proportion of enrolled subjects completing the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Residual anti-pneumococcal immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cTOI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cFTOE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cTHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ICON
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delays in obtaining Class I canine right and left
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reovirus tumour infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bladder volume achievement within +/- 30% of planning volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tolerability and safety of UT-15C tablets
Endpoint domain: Adverse events/effects
Primary endpoint: Il-6 secretion in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Indicators of Oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Markers of axonal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MS-relevant cytokines, chemokines and osteopontin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phenotype and activation status of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient satisfaction with breast surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Care Path Behavioral Assessment (CPBA) Pre-surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Care Path Behavioral Assessment (CPBA) Post-surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline of PSG latency to persistent sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of PSG wake after sleep onset (WASO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Access safety
Endpoint domain: Adverse events/effects
Primary endpoint: Closure safety
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients who quit previous medication for diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who quit previous medication for hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain reduction during cavity preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly Research study completion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in serum phosphorous
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Auto-fluorescence image assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Quigley Hein plaque index modified by Turesky
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICDAS scoring results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in unprotected sex risk with high risk partners
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Failure of internal fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IL-6 response to psychological stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Score at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Analog Scale (VAS) Score for Pruritus at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin color change after UV irradiation at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin transepidermal water loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin erythema and melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Mean Percent of Parent Child Dyadic Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in FA (fractional anisotropy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Satisfaction with postoperative pain control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum albumin-adjusted calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum parathyroid hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: coronary artery tortuosity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in [11C]PBR28 Distribution Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circulating metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Participants Abstinent From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Had One or More Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Asthma Control Questionnaire (ACQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in Asthma Controlled Test (ACT) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resting Motor Thresholds (rMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in medication rate adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of appearance of endogenous glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of UPDRS III scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvement of PDQ-39 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response to initial resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childrens Depression Rating Scale - Revised (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in airway resistance (Raw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Eligible Participants Refusing to Participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contrast Enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Breakthrough Varicella
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Breakthrough Varicella
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: change in quality of life overall summary scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Craving on the Alcohol Urge Questionnaire (AUQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gait Quality as Indicated by Joint Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle Function as Indicated by EMG Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Expenditure During Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assay inter-instrument variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Establish normal ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Positive Results of T-SPOT.TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of renal functional reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients With Lack of Objective Clinical Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline rate of serum AMH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ASAS20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reports of abnormal physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reports of abnormal laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Snoring Relationship Questionnaire (SRQ)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: microvascular blood flow (MBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: capillary RBC velocity (CBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Numbers of vaccine high responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient-rated therapeutic alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vasodilatory Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement or no further progression of motor deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Blood Tests for Bilirubin Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Negativity of HCV RNA below 12UI/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Graft-versus-host disease (GvHD) free relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Arteriosclerosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Arteriolar Hyalinosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Interstitial fibrosis and tubular atrophy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Continuous percentage of sclerotic glomeruli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ovarian function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Anterior Cingulate Gyrus Activation During Working Memory Processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes